Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial

BACKGROUND: To determine the minimum survival benefits that patients, and their clinicians, judged sufficient to make adjuvant chemotherapy (ACT) worthwhile, in addition to pelvic radiotherapy, for women with high risk and advanced stage endometrial cancer. METHODS: Eighty-three participants in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Blinman, Prunella, Mileshkin, Linda, Khaw, Pearly, Goss, Geraldine, Johnson, Carol, Capp, Anne, Brooks, Susan, Wain, Gerard, Kolodziej, Ilka, Veillard, Anne-Sophie, O'Connell, Rachel, Creutzberg, Carien L, Stockler, Martin R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5104894/
https://www.ncbi.nlm.nih.gov/pubmed/27764842
http://dx.doi.org/10.1038/bjc.2016.323

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5104894/
https://www.ncbi.nlm.nih.gov/pubmed/27764842
http://dx.doi.org/10.1038/bjc.2016.323

Ejemplares similares